STEMI介入术中冠脉内不同部位应用重组人尿激酶原的疗效观察  

The clinical curative effects of recombinant human prourokinase in different positions of patients with ST-segment elevation myocardial infarction(STEMI)undergoing percutaneous coronary intervention(PCI)

作　　者：王德良[1] 王新华[1] 裴建行[1] 贾涵铄 董京京[1] 张苗苗 马光[1] WANG Deliang;WANG Xinhua;PEI Jianxing(Department of Cardiology,The Second Central Hospital of Baoding City,Hebei,Baoding 072750,China)

机构地区：[1]河北省保定市第二中心医院心内一科,072750

出　　处：《河北医药》2021年第2期231-234,共4页Hebei Medical Journal

基　　金：保定市科学技术研究与发展计划(编号:20412F032)。

摘　　要：目的探讨冠脉内不同部位重组人尿激酶原(rh-proUK)在急性ST段抬高型心肌梗死(STEMI)介入中的疗效观察。方法选取保定市第二中心医院在2018年3月至2019年3月诊断为STEMI并拟行PCI术的患者82例。将82例患者随机分为指引导管给药组(A组,n=40)和靶向给药组(B组,n=42),将rh-proUK 20mg分别通过指引导管和靶向导管注入2组患者中,然后植入支架。记录患者一般资料、血流恢复情况,心功能指标,主要心血管不良事件(MACE)发生率等。结果PCI术后,B组在术后血流恢复情况,心电图,心肌坏死标志物,心功能改善情况等均优于A组(P<0.05),2组MACE和出血事件发生率差异无统计学意义(P>0.05)。结论与指引导管给药相比较,经靶向导管给药可进一步改善STEMI患者PCI术的溶栓效果及预后情况。Objective To investigate the curative effects of recombinant human prourokinase in different positions of patients with ST-segment elevation myocardial infarction(STEMI)undergoing percutaneous coronary intervention(PCI).Methods A total of 82 patients with STEMI who were scheduled to receive PCI in our hospital from March 2018 to March 2019 were enrolled in the study,who were randomly divided into guided catheter medication group(group A,n=40)and targeted catheter nedication group(group B,n=42).The Rh-proUK 20mg was injected into the patients in the two groups through different catheter medication ways,then the stents were implanted.The general clinical data of patients,and the recovery status of blood flow,cardiac function indexes,and the incidence rate of major adverse cardiovascular events(MACE)were observed and compared between the two groups.Results After PCI operation the postoperative blood flow recovery status,electrocardiogram,myocardial necrosis markers,and cardiac function improvement in group B were superior to those in group A(P<0.05),however,there were no significant differences in the incidence rates of MACE and bleeding events between the two groups(P>0.05).Conclusion As compared with the guided catheter medication,the target catheter medication can improve the thrombolytic effects and prognosis of patients with STEMI undergoing PCI.

关 键 词：ST段抬高型心肌梗死 经皮冠脉介入治疗 重组人尿激酶原 

分 类 号：R542.22[医药卫生—心血管疾病]